Results of a pilot clinical trial of the safety and efficacy of an original glycoprotein IIb/IIIa receptor inhibitor in acute coronary syndrome

Aim. To study the safety and efficacy of Angipure in acute ST-segment elevation coronary syndrome (STE-ACS) high-risk percutaneous transluminal angioplasty (PTCA) compared with eptifibatide. Material methods . The included 157 patients STE-ACS. High-risk PTCA massive or total artery thrombosis, noreflow/slow-reflow phenomenon, stent thrombosis. Fifty-five people received at a dose 0,72 mg/kg, 52 — 0,40 while 50 eptifibatide (Integrilin). We conducted clinical laboratory studies, electrocardiography (ECG), angiography. Results. According to criteria "Frequency severity hemorrhagic events, including stroke", "Frequency, other adverse events", there were no differences between doses mg/kg Complaints, symptoms, vital signs, complete blood count, biochemical coagulation tests, ECG different groups similar had unidirectional dynamics. use was considered effective if outcomes (death, recurrent ischemic event, need for urgent revascularization) observed within 30 days. There lethal outcomes. One repeated event registered each group. In receiving eptifibatide, revascularization required once each. Conclusion. have efficacy.